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GADOLINIUM CHELATES AS NMR CONTRAST
AGENTS
BACKGROUNDOF THE INVENTION
The present invention relates to NMR imaging of
living subjects. More specifically, it relates to agents
which can be used to enhance NMRcontrast in such
subjects.
Nuclear magnetic resonance (NMR) has been used
for many years as a means of chemical analysis. NMRis
a type of radio frequency spectroscopy which is based
upon small energy differences between electrically
charged atomic nuclei which are spinning parallel or
antiparallel to an applied magnetic field. When radio
frequency energy is applied to the sample, these spin-
ning atomic nuclei change spin states and in doingso,
absorb some of the radio frequency energy. Nuclei in
slightly different chemical environments within the
same molecule change spin state at slightly different
energies and this produces characteristic absorptions or
resonances whichhelp identify the molecular structure.
NMRhas morerecently been used in examinations of
the human body. Other methods such as computerized
axial tomography (CAT scanning) have been used in
the past for this purpose, and still are. However, be-
cause NMRdoes not use ionizing radiation, it is be-
lieved to have somesafety advantages over CAT. Thus,
NMRis an advantageous method of producing cross-
sectional images of the human body.
The quality of the images obtained from an NMR
scan are based on two properties: the proton densities of
the various tissues and differences in proton relaxation
rates. The proton density of tissues cannot be readily
altered. Proton relaxation rates can be adjusted by add-
ing a paramagnetic relaxation agent, more commonly
knownas a “contrast agent.’ Contrast agents enhance
the contrast in NMR images between magnetically
similar but histologically dissimilartissues.
Gadolinium has been tested as a contrast agent in the
past because it has a large magnetic moment, which
efficiently relaxes magnetic nuclei. Gadolinium’s strong
paramagnetic properties are the result of its seven un-
paired electrons. ,
One drawback of gadolinium as a contrast agentisits
toxicity to animals. One possible remedy for this prob-
lem is to incorporate gadolinium in a compoundthat
would pass through the body and be excreted without
releasing toxic gadolinium ions. Unfortunately, the rare
earth elements, such as gadolinium, do not form stable
covalent bonds with organic molecules, so such mole-
cules can decompose in vivo andrelease the toxic ions.
Complexes of gadolinium might overcome this prob-
lem.
There is a need for effective contrast agents which
avoid the toxicity problems inherent in using gadolin-
ium.
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SUMMARYOF THE INVENTION
_ The present invention concerns NMR _contrast
5 agents which include a chelate of gadolinium with
either 1,4,7-triazacyclononane-N,N’,N’’-triacetate
(NOTA),  1,4,7,10-tetrazacyclododecane-N,N’,N",N’”
tetracetate (DOTA), or 1,5,9-triazacyclododecane-
N,N’,N"-triacetate (DOTRA), or salts thereof. When
the phrase “salts thereof’ is used in this patent, it means
that one of the acidic hydrogen ions on an acetate
group has been replaced by anothercation, not that an
entire acetate group has been replaced. The particular
juxtaposition of the nitrogen and oxygen atoms has an
important effect on the chelating properties of NOTA,
DOTA, and DOTRA,so removal of an entire acetate
group would harm that property. Of course, upon
dissolving ‘the chelate in solution, the cation that has
replace a hydrogen ion would dissociate leaving the
samecentral ionic species.
These contrast agents can be used to enhance NMR
contrast in a living subject by administering internally
to the subject an effective amountofthe agent. “Admin-
istering internally” is intended to include methods such
as injection, ingestion, or the like which would be
knownto one skilled in this field.
DOTRA, DOTA, and NOTAreduceor prevent the
toxic effects of the Gd3+ cation to in vivo processes by
firmly complexing with i. DOTRA and DOTA form
gadolinium chelates that are especially stable, with
NOTA binding somewhatless firmly, possibly due to
the small size of the “hole” in NOTA’s molecule.
This binding strength should result in very low bio-
logical toxicity for contrast agents in accordance with
the present invention. In addition, the agents appear to
have substantially better relaxation properties than
some prior art agents, which will permit the use of a
smaller amountofthe agents to achieve the sameeffect.
DETAILED DESCRIPTION OF SPECIFIC
EMBODIMENTS OF THE INVENTION
The following is a procedure which can be used to
synthesize NOTA:
Step 1: Synthesis of N,N',N’-tri(p-toluenesulfonyl)-
diethylene-triamine
A solution of p-toluenesulfonyl chloride (191 g) in
ether (500 ml) was added drop by drop to a solution of
diethylene triamine (38 m1) and sodium hydroxide (40 g)
in water (250 ml). The mixture was stirred for one hour
at room temperature. A white precipitate was formed
and wascollected byfiltration, washed with water, and
then recrystalized using methanol. (Acetonitrile could
also be used). The melting point of the recrystalized
precipitate was 174° to 175° C. The yield was 90%, and
should always be above 70%.
Step 2: Synthesis of di(p-toluenesulfonylethylene
glycol
Twenty-eight ml of ethylene glycol and 100 ml of
pyridine were added overa 2.5 hourperiod to a stirred
mixture of tosyl chloride (210 g) in pyridine (225 ml),
with the mixture being cooled by a water bath. After
stirring for several hours, the mixture was shaken with
one liter of ice water for about ten minutes and then
filtered. The residue was washed with ether, dilute
sulfuric acid, water, and finally ether. (Each of the
washed liquids was ice cold.) The residue was then
dried by vacuum pumpingand recrystallized from boil-
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ing acetonitrile. The recrystallized residue, yield 75%,
had a melting point of 123° to 125° C.
Step 3: Preparation of the disodiom salt of N,N’,N”-
tri(p-toluenesulfonyl)diethylene triamine
Eachpartofthis step was conducted undera nitrogen
atmosphere. 2.65 grams of sodium metal was weighedin
hexane and placed in about 75 ml of pure ethanol. The
sodium-ethanol reaction is highly exothermic, and the
heat helps dissolve the sodium to give sodium ethoxide.
A hotslurry of 1,4,7-tritosyl-1,4,7-triazaheptane (28.3 g)
from Step 1 and 150 ml of ethanol wasstirred in a reac-
tion vessel with a reflux condenser. The slurry was
heated to reflux using an oil bath, and then the sodium
ethoxide was addedas rapidly as possible. After contin-
ued stirring and flushing with nitrogen, a white solid
precipitated. Slight heating and flushing continued until
all the ethanol was removed and the dry disodium salt
of 1,4,7-tritosyl-1,4,7-triazaheptane wasleft.
Step 4: Synthesis of 1,4,7-triazacyclononane-
N,N’,N”-tritosylate
This step was conducted without removing the dry
salt from the Step 3 reaction vessel. The dry disodium
salt was dissolved in 225 ml of dry dimethy! formamide
(DMP), once again under a nitrogen atmosphere. The
mixture wasstirred and heated to 95° to 110° C. Next, a
0.2M solution of ethylene glycolditosylate (18.5 g) in
. DMFwasaddedovera period of three hours. After one
additional hourofstirring at 100° C., the mixture was
cooled overnight. It was then concentrated by distilla-
tion under reduced pressure until precipitation began.
“The concentrate was poured into 500 mls of vigorously
stirred water and filtered. The residue was washed with
“water, dried by vacuum pumping, and recrystallized
from boiling acetone. The product, 1,4,7-triazacyclono-
nane-N,N’,N"'-tritosylate, had a melting point of 217° to
220° C. and was present in a yield of 70%.
Step 5: Synthesis of 1,4,7-triazacyclononanetrihydro-
bromide
One hundred twenty ml of a mixture of 47% HBr, 67
-ml of glacial acetic acid, 13.99 g of the product of Step
‘4 were heated to 100° C., and the volume was then
remeasured. The mixture was then refluxed for fifty
hours and concentrated by atmospheric distillation to
about 20% of the beginning volume. The concentrate
was then filtered. The residue, containing 1,4,7-
triazacyclononane-N,N’,N”-trihydrobromide, was ex-
tracted into water and then recovered by evaporation in
vacuo. The trihydrobromide was recrystallized from
boiling hydrobromicacid. Its melting point was 280° C,
and it was present in 70% yield. Tosylate groups were
completely absent in the NMR spectra of the trihydro-
bromide.
Step 6: Synthesis of
N,N’,N”-triacetete (NOTA)
1,4,7-triazacyclononane-
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A solution of 4.72 g of bromoacetic acid and 1.2 g of 55
sodium hydroxide in 10 ml of water was added with
stirring to a solution of 3.72 g of the product of Step 5
and 1.2 g of sodium hydroxide in 3.5 ml of water at
about 20° C. The mixture was heated to 85° C. with an
oil bath while being stirred, and then 1.2 g of sodium
hydroxide, dissolved in 6.5 ml of H20, was added drop-
wise with stirring. The temperature was maintained
between 80° to 90° C. for one and one-half hours. The
contents of the flask were then cooled to room tempera-
ture and the pH wasadjusted to about 3.5 with concen-
trated hydrobromic acid. 25 ml of ethyl alcohol was
added, and the solution was stirred for an hour under
refrigeration. A white crystalline precipitate formed
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which wasfiltered out, washed with pure ethanol, and
dried in a vacuum ovenat 70° C. overnight. This prod-
uct was NOTA,and the 2.5 g of it represented an at
least 70% yield.
Elemental analysis showed close correspondence to
what was expected for Cj2H21;0¢6N3 (NaBr)3.3H20.
Calculated: 25.58% C, 4.79% H, 7.46% N,28.42% Br,
and 8.17% Na. Found: 25.39% C, 4.89% H, 7.43% N,
28.44% Br, and 8.00% Na.
This synthesis can be summarized as shown below.
Step |ON
HN + 3NaOH + 3TsCl ——>
Cnn
*
NH
TsN + 3H2O + 3NaClrr
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-continued
Step 5
‘ \ Br- } \ Br-
Ht—N Nt+t—H
HBr > \a ut
acetic i
acid Nt
|H
Br-
[oN Step 6
Br~H2Nt+ =+NH2Br~ NaOH
Nat+—-OOCH2Br
C2HsOH
Nt.
HBr—
Nat+—-OOCH2C / \ CH,COO~Nat\r~ +NH HN+Br—
« ) .3H20
NHI
Br-
CH,COO-Nat
DOTAand DOTRA can besynthesized using gener-
ally the same procedure, but starting with triethylene
tetraamine instead of diethylene triamine to synthesize
DOTA and dipropylene triamine and 1,3 propanediol
instead of diethylene triamine and ethylene glycol, re-
spectively, for synthesizing DOTRA. The remaining
reagents would be identical with only the stoichiomet-
ric quantities varying for DOTA.
Once DOTA, NOTA or DOTRA hasbeen obtained
in crystalline form, a measured amountofit is dissolved
in water and an equimolar amountof a gadolinium salt,
such as gadolinium chloride or gadolinium nitrate, is
added to the solution. The Gd-NOTA complex forms
spontaneously above pH 5 while the Gd-DOTA and
Gd-DOTRA complexes are kinetically slower to form
and may require heating to 80° C. for 30 minutes to
increase the rate of chelation.
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Salts of DOTA, NOTA and DOTRA could, of
course, also be used, since the counter ions will dissoci-
ate in solution. What synthetic procedure is most conve-
nient may dictate whichsalt to use. The megluminesalt
of Gd-DOTA, Gd-NOTA or Gd-DOTRA is one
which should be useful in contrast agent formulations.
The contrast agents could be formulated as a saline
solution and packagedin bottles having a rubber septum
across the opening to permit withdrawing the solution
with a syringe.
Contrast agents in accordance with the present inven-
tion can be used with NMR apparatus which are well
knownto those skilled in this field. Examples of U.S.
patents which disclose NMR apparatus are U.S. Pat.
Nos. 4,374,360; 4,398,148; 4,409,550; 4,425,547;
4,442,404; and 4,450,408, all of which are incorporated
herein by reference. NMR imaging should probably be
done within a few hours after administering the contrast
agent to the subject, since the agent should be excreted
from the bodyfairly rapidly.
The preceding is intended to illustrate specific em-
bodiments of the present invention, and not to be an
exhaustive description of all possible embodiments.
Those skilled in this field will recognize that certain
modifications could be made.
I claim:
1. A method of enhancing NMR contrast in a living —
subject, comprising administering internally to the sub-
ject an effective amountofa contrast agent which com-
prises a chelate of gadolinium with a. compoundse-
lected from the group consisting of DOTRA, DOTA,
NOTA,andsalts thereof.
2. A method of enhancing NMRcontrast in a living
subject, comprising administering internally to the sub-
ject an effective amount of a contrast agent which com-
prises a chelate of gadolinium with DOTRA ora salt
thereof.
3. A method of enhancing NMRcontrast in a living
subject, comprising administering internally to the sub-
ject an effective amount of a contrast agent which com-
prises a chelate of gadolinium with DOTAora salt
thereof.
4. A method of enhancing NMRcontrast in a living
subject, comprising administering internally to the sub-
ject an effective amountofa contrast agent which com-
prises a chelate of gadolinium with NOTA ora salt
thereof.
* * * * *
